EHSI — what changed in the latest 10-Q
A section-by-section comparison of EHSI's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-05-20 vs the prior 10-Q · 2025-11-13
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +6 | −15 | ~7 | 11 |
| Controls & procedures | Text added/removed | +1 | −1 | ~2 | 6 |
| Legal proceedings | Text added/removed | +1 | 0 | 0 | 1 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Market risk (Item 3), Risk factors, Other information
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-05-20
The Condensed Consolidated Financial Statements of Elite Health Systems Inc. and subsidiaries (the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America. As such, some accounting policies have a significant impact on amounts reporte…
During the three months ended March 31, 2026 and 2025 the Company recorded no income tax benefit or provision.
For the three months ended March 31, 2026, the Company reported a net loss of $1,355,000 as compared to $424,000 for the same period a year earlier. The net loss was primarily due to the acquisition of PSS.
Net cash used in operating activities for the three months ended March 31, 2026, was $1,256,000 as compared to $461,000 for the same period a year earlier. This change is primarily due to the Company’s acquisition of PSS and higher expenses of EHP now that the plan has begun operations.
The Company raised total proceeds of an aggregate of $100,000 and $474,000 during the quarters ended March 31, 2026 and 2025, respectively. As a result of these issuances, as of March 31, 2026, there were outstanding 28,521,620 shares of the Company’s Common Stock.
Text removed vs the prior filing · source: 10-Q · 2025-11-13
Management Discussion and Analysis of Financial Condition and Results of Operations.
The Condensed Consolidated Financial Statements of Elite Health Systems Inc. and subsidiaries (the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America. As such, some accounting policies have a significant impact on amounts reporte…
During the three months ended September 30, 2025, the Company recognized no change from its investment in unconsolidated entities compared to a gain of $97,000 during the same period in 2024.
During the three months ended September 30, 2025 and 2024, the Company recorded no income tax benefit or provision.
For the three months ended September 30, 2025, the Company reported a net loss of $1,165,000 as compared to $290,000 for the same period a year earlier. The net loss was primarily due to investment in Elite prior to generation of any revenue.
Controls & procedures
Text added vs the prior filing · source: 10-Q · 2026-05-20
Our management assessed the effectiveness of the Company’s internal control over financial reporting as of March 31, 2026. A material weakness is a control deficiency, or a combination of control deficiencies in internal controls over financial reporting, such that there is a reasonable possibility …
Text removed vs the prior filing · source: 10-Q · 2025-11-13
Our management assessed the effectiveness of the Company’s internal control over financial reporting as of September 30, 2025. A material weakness is a control deficiency, or a combination of control deficiencies in internal controls over financial reporting, such that there is a reasonable possibil…
Legal proceedings
Text added vs the prior filing · source: 10-Q · 2026-05-20
The Company is subject to lawsuits, investigations and potential claims arising out of the ordinary conduct of its business. The Company is not currently involved in any material litigation.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice